Filing Flows › Anika Therapeutics (ANIK) › Q1 2026
Anika Therapeutics (ANIK) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 30, 2026
Anika Therapeutics (ANIK) reported revenue of $29.6M for the first quarter 2026 (Q1 2026), +13% from a year earlier and -3% from the quarter before. Operating margin was -18.5%, net loss $5.1M (17.1% of revenue).
Anika Therapeutics, Q1 2026: revenue $29.6M (+13% year over year), operating margin -18.5%, net loss $5.1M, operating cash flow −$4.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29.6M | -3% | +13% |
| Operating profit | −$5.5M | -950% | — |
| Net earnings | −$5.1M | -1832% | — |
| Operating cash flow | −$4.8M | -205% | — |
What changed
Revenue was $29.6M in Q1 2026, up 13% year over year and down 3% from the previous quarter. OEM Channel was the largest line at 58% of revenue. OEM Channel added $2.1M year over year (up 14%), 62% of the total change.
Gross margin was 64.2%, up 8.1 points from Q1 2025. Operating costs exceeded revenue by $5.5M, an operating margin of -18.5%. Operating expenses grew 29% against revenue growth of 13%. The fastest-growing cost line was SG&A (+38%). The quarter ended with a net loss of $5.1M, after a profit of $292K the previous quarter.
Operating cash flow was −$4.8M. Non-cash charges added back $1.4M of depreciation and amortization and $6.6M of share-based compensation. Working capital and other items used $7.8M. Capital expenditures of $1.4M exceeded it, leaving free cash flow of −$6.3M.
Questions
What was Anika Therapeutics' revenue in the first quarter 2026?
Anika Therapeutics (ANIK) reported revenue of $29.6M for the first quarter 2026 (Q1 2026), +13% from a year earlier and -3% from the quarter before.
Was Anika Therapeutics profitable in the first quarter 2026?
Operating loss was $5.5M (-18.5% of revenue) and net loss $5.1M.
Source: Anika Therapeutics 10-Q on SEC EDGAR.